Galen Growth and FINN Partners Will Release the First “Global State of Digital Health Report” this November at HLTH

Galen Growth, a leading digital health, data-driven market intelligence company, and FINN Partners, a global integrated marketing services agency, announced a joint effort to mine data and produce the first “Global State of Digital Health Report.” The first report drawing input from some 200M data points and more than 12,000 digital health ventures across the globe, will be released at the November HLTH Conference in Vegas, NV. The second report will be available in January 2023 at the JP Morgan Healthcare Conference in San Francisco, CA, as part of the Future & Health Event. Additional quarterly reports are anticipated throughout the coming year.

“FINN Partners is thrilled to pair with Galen Growth to take a deeper look at the Digital Health landscape,” said Ritesh Patel, Senior Partner, Global Digital Health Lead at FINN Partners. “The rapidly expanding digital health ecosystem must be leveraged to improve patient outcomes. This series of studies will help inform the choices providers, payers, product innovators, and patients will need to make in the coming years.”

FINN Global Digital Health Group are working side-by-side with Galen Growth data and research professionals to chart the complex and often fragmented digital health landscape; emerging market trends, areas of growth and innovation, and look beyond equity funding to explore what’s expected to happen in this fast-paced digital health sector. The combined team will look beyond the “hype” of digital to map the priority and practical opportunities for decision-makers.

Often public reports tend to cherry-pick data. The Galen/FINN “Global State of Digital Health Report” shows verified trends, including:

  • While 2022 digital health venture capital has not matched the skyrocketing value of 2021, a closer look at year-on-year Q1 – Q3 funding by development stages reveals that capital infusion in 2022 exceeds 2021 values for the Early Stage and Series A funding rounds. It increasingly lagged in 2021 values across later funding stages.
  • More than 60% share of the total venture funding value comes from North America. But on a regional level, the Middle East set record-breaking amounts of venture funding in Q2 2022. Europe maintains momentum throughout 2022 and has not experienced the quarter-on-quarter decrease in venture funding seen in North America.

In the shadow of the pandemic, tremendous investment poured into digital health. The digital health sector has grown significantly during the past decade, with $2 billion invested in 2011 and $44 billion in 2021 by the global financial and corporate markets. But in the past year, investors have been more selective in their decisions. The “Global State of Digital Health Report” will examine those shifts and outline best practices in investment strategies.

“With the slowdown of venture funding in 2022, digital health is anchoring back to reality, becoming more focused, and demanding more verification that ventures are offering solutions that will bring value to the digital health ecosystem,” said Julien de Salaberry, CEO and Galen Growth co-founder. “This joint report with FINN Partners will explore how ventures are meeting those challenges and preparing to show evidence to demonstrate the effectiveness of their solutions.”

The first of the two reports will lay the groundwork for future reports recapping the year-to-date in digital health and focus on global investment insights, categories, and therapeutics, to name a few themes that hold great potential to benefit from digital applications and 2023 trends.

FINN digital health leaders will lend their perspective, analysis, and guidance to supplement the data and insights developed by the Galen Growth team to help guide stakeholders as they navigate and engage with the global digital health landscape.

“The health system has been long resistant to change. Health information—delivered across digital platforms—has altered the patient care pathway and shifted the tone and expectation among decision-makers navigating the fragmented health ecosystem,” said Gil Bashe, Chair Global Health and Purpose, FINN Partners. “The Galen Growth/FINN Partnership will offer insights to the sector—private and public—that will hopefully rally investors and innovators to ideas that can sustain and save lives faster.”

Ads

You May Also Like

What Trump’s Win Might Mean for Pharma

First, let’s acknowledge the obvious—nobody knows what Trump’s win might mean for the pharma ...

PM360 Announces Winners of 2015 Trailblazer Awards

PM360 recognized the best innovators in the pharmaceutical and medical device industries with their ...